Slama R
Clinique cardiologique de l'Hôpital Lariboisière, Paris.
Bull Mem Acad R Med Belg. 1994;149(8-11):383-7; discussion 387-8.
Thanks to the fantastic job made by Michel Mirowski, the automatic implantable cardioverter-defibrillator is now an effective treatment for patients with malignant, life-threatening arrhythmias. And in the last ten years, many technical improvements have been made (weight, size, reconfirmation, Holter function, endocardial implantation). But if sudden death has been significantly reduced in implanted patients, the long term global cardiac mortality remains very high in these people. This explains why the indications to implant such an expensive device are difficult to define. Apart from special cases in which the indications (or contraindications) are obvious, many factors must be taken into consideration, including the presentation of the arrhythmia, the results of the programmed ventricular stimulation, and the underlying cardiac disease. The European society of Cardiology has published guidelines for the use of A.I.C.D., but from our own experience in Hospital Lariboisière (Paris, France) we have learned that each case must be discussed; and, if it is possible to suggest some therapeutic orientations, it is yet illusory to believe that decisional algorithms will solve all the problems.
多亏了米歇尔·米罗夫斯基所做的出色工作,自动植入式心脏复律除颤器如今已成为治疗恶性、危及生命的心律失常患者的有效手段。在过去十年中,该设备有了许多技术改进(重量、尺寸、重新确认、动态心电图监测功能、心内膜植入)。然而,尽管植入该设备的患者猝死率显著降低,但这些患者的长期总体心脏死亡率仍然很高。这就解释了为何难以界定植入这种昂贵设备的适应症。除了适应症(或禁忌症)明显的特殊情况外,必须考虑许多因素,包括心律失常的表现、程控心室刺激的结果以及潜在的心脏疾病。欧洲心脏病学会已发布了使用自动植入式心脏复律除颤器的指南,但根据我们在法国巴黎拉里博伊斯医院的经验,我们认识到每个病例都必须进行讨论;而且,尽管有可能提出一些治疗方向,但认为决策算法能解决所有问题仍是不切实际的幻想。